News Release: Vitalis Acquires Campus Adjacent MOB in Cincinnati, Ohio for $6,400,000.

The transaction closed on September 22nd, 2022.

Vitalis closed on a 16,500 SF campus adjacent medical office building located at 4665 E. Galbraith Road in Cincinnati, OH. The building sold for $6,400,000 or $387 / SF and closed off-market. Infiniti Dialysis, Nephrology Associates of Greater Cincinnati, Bernstein Allergy & Bernstein Clinical Research occupy 100% of the facility on long term NNN leases. The building was developed in 2020 across from the Mercy Hospital campus in Cincinnati.

Bernstein Clinical Research Center is known nationally for their work in Allergy and Immunology performing over 900 clinical trials since 1969. Infinity Dialisis and Nephrology Associates are multi-location kindey specailists serving patients in Ohio, Indiana and Kentucky.

“We are excited to close on this asset in Cincinnati where campus adjacent medical office has a high barrier of entry for healthcare real estate investors ” says Managing Director Elliot LaBreche. “We look forward to a long term relationship with the developer and operator of Infinity Dialysis to accelerate their grow within the region”.

Vitalis plans to accelerate the pace of acquisitions in Top 50 metropolitan areas with a goal of closing $150,00,000 in Medical Office and Life Science by the end of 2022.

# # # #

About Vitalis:

Elliot LaBreche is the founder of Vitalis, a vertically integrated real estate investment company focused on medical office and life science investment sales, acquisitions, and leasing across the US.

About Advenir:

Stephen Vecchitto, founded Advenir in 1996 and serves as the company’s Managing Director. Advenir acquires, develops, and manages multi-family and single-family rental communities on behalf of high net worth and institutional investors. Advenir’s current multi-family portfolio consists of 15,000 units valued at over $3 Billion.

The full content of this article is only available to paid subscribers. If you are an active subscriber, please log in. To subscribe, please click here: SUBSCRIBE

Existing Users Log In
   

Balloonacy1